280 related articles for article (PubMed ID: 25026281)
21. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
22. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
23. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
24. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
25. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.
Yu Y; Yu X; Fan C; Wang H; Wang R; Feng C; Guan H
J Mol Med (Berl); 2018 Aug; 96(8):777-790. PubMed ID: 29942976
[TBL] [Abstract][Full Text] [Related]
26. T Helper Cell Activation and Expansion Is Sensitive to Glutaminase Inhibition under Both Hypoxic and Normoxic Conditions.
Sener Z; Cederkvist FH; Volchenkov R; Holen HL; Skålhegg BS
PLoS One; 2016; 11(7):e0160291. PubMed ID: 27467144
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma.
Zhang T; Cui Y; Wu Y; Meng J; Han L; Zhang J; Zhang C; Yang C; Chen L; Bai X; Zhang K; Wu K; Sack MN; Wang L; Zhu L
Clin Transl Med; 2022 May; 12(5):e852. PubMed ID: 35538890
[TBL] [Abstract][Full Text] [Related]
28. The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers.
Basheer HA; Elsalem L; Salem A; Tailor A; Hunter K; Afarinkia K
Curr Cancer Drug Targets; 2022; 22(2):169-179. PubMed ID: 34951574
[TBL] [Abstract][Full Text] [Related]
29. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L; Jacque N; Jacquel A; Neveux N; Maciel TT; Lambert M; Schmitt A; Poulain L; Green AS; Uzunov M; Kosmider O; Radford-Weiss I; Moura IC; Auberger P; Ifrah N; Bardet V; Chapuis N; Lacombe C; Mayeux P; Tamburini J; Bouscary D
Blood; 2013 Nov; 122(20):3521-32. PubMed ID: 24014241
[TBL] [Abstract][Full Text] [Related]
31. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
33. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
34. Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.
de Los Santos-Jiménez J; Campos-Sandoval JA; Márquez-Torres C; Urbano-Polo N; Brøndegaard D; Martín-Rufián M; Lobo C; Peñalver A; Gómez-García MC; Martín-Campos J; Cardona C; Castilla L; da Costa Souza F; Cheng T; Segura JA; Alonso FJ; Curi R; Colquhoun A; DeBerardinis RJ; Márquez J; Matés JM
J Biomed Sci; 2021 Feb; 28(1):14. PubMed ID: 33610185
[TBL] [Abstract][Full Text] [Related]
35. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin.
Torricelli C; Daveri E; Salvadori S; Valacchi G; Ietta F; Muscettola M; Carlucci F; Maioli E
Cancer Lett; 2015 Apr; 360(1):17-27. PubMed ID: 25661734
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of glutaminase 2 in human liver and colon cancers.
Zhang J; Wang C; Chen M; Cao J; Zhong Y; Chen L; Shen HM; Xia D
BMC Cancer; 2013 Dec; 13():601. PubMed ID: 24330717
[TBL] [Abstract][Full Text] [Related]
38. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation.
Qie S; Chu C; Li W; Wang C; Sang N
J Cell Biochem; 2014 Mar; 115(3):498-509. PubMed ID: 24122876
[TBL] [Abstract][Full Text] [Related]
39. LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer.
Xu P; Oosterveer MH; Stein S; Demagny H; Ryu D; Moullan N; Wang X; Can E; Zamboni N; Comment A; Auwerx J; Schoonjans K
Genes Dev; 2016 Jun; 30(11):1255-60. PubMed ID: 27298334
[TBL] [Abstract][Full Text] [Related]
40. Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK.
Avivar-Valderas A; Bobrovnikova-Marjon E; Alan Diehl J; Bardeesy N; Debnath J; Aguirre-Ghiso JA
Oncogene; 2013 Oct; 32(41):4932-40. PubMed ID: 23160380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
